Global Thrombocytopenia-Absent Radius (TAR) Syndrome Market – Industry Trends and Forecast to 2030

혈소판감소증-무반경(TAR) 증후군 시장 분석 및 규모

혈소판 감소증-반경 결손(TAR) 증후군은 출생 시에 나타나는 희귀 질환의 일종입니다. 영향을 받은 개인의 약 90%가 생후 1년 동안 혈액 내 혈소판 수치가 낮아지는 증상을 보입니다. TAR 증후군의 발생률은 1:200,000-1:100,000으로 추산됩니다. 이 질환은 원래 1950년대에 형제 자매에게서 설명되었습니다. 그 이후로 100건 이상의 사례가 기록되었습니다.

Data Bridge Market Research는 2023-2030년 예측 기간 동안 혈소판 감소증-반경 결손(TAR) 증후군 시장의 성장률을 분석합니다. 혈소판 감소증-반경 결손(TAR) 증후군 시장의 예상 CAGR은 언급된 예측 기간 동안 약 13%인 경향이 있습니다. 이 시장은 2022년에 9억 4천만 달러로 평가되었으며 2030년까지 25억 달러로 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

혈소판감소증-무반경(TAR) 증후군 시장 범위 및 세분화

시장 정의

혈소판 감소증-반경 결손(TAR) 증후군은 응고에 관여하는 혈액 세포가 부족하고 각 팔뚝에 반경골이라는 뼈가 없는 것으로 알려져 있습니다. 이 혈소판 부족은 일반적으로 어린 시절에 발생하여 점진적으로 개선됩니다. 혈소판 수치는 많은 상황에서 정상으로 돌아올 수 있습니다. 뇌와 다른 장기의 극심한 출혈은 특히 생후 첫해에 생명을 위협할 수 있습니다. 이 기간을 살아남고 뇌출혈을 겪지 않는 일부 영향을 받은 어린이는 정상적인 수명과 지적 발달을 보입니다.  

혈소판감소증-무반경(TAR) 증후군 시장 역학

운전자

• 진단 절차 증가

많은 경우, TAR 증후군의 진단은 자세한 임상 검사, 특징적인 신체적 발견의 확인 및 수많은 전문 검사를 기반으로 출생 시에 이루어집니다. 이러한 검사는 혈소판 감소증, 빈혈 또는 기타 혈액학적 이상의 존재와 전완의 방사선 사진 및 신장의 신장 초음파 검사를 확인하는 데 사용됩니다. 심장 평가는 장애와 관련된 모든 종류의 심장 이상을 감지하기 위해 권장될 수도 있습니다. 이러한 종류의 평가에는 청진기를 사용하여 심장 및 폐 소리를 평가하는 임상 검사 와 의사가 심장의 구조와 기능에 접근할 수 있도록 하는 여러 가지 전문 검사가 포함될 수 있습니다. 따라서 시장 성장을 촉진합니다.

기회

• 증가하는 치료 방법

The wide treatments for thrombocytopenia-absent radius (TAR) syndrome are being researched and developed recently. Several physicians may recommend preventive measures to help the affected infants and children to avoid infection, stress, or other factors that may precipitate thrombocytopenia. In addition to this, specialists specify that cow’s milk should be avoided, since its introduction may precipitate thrombocytopenic, eosinophilic, or “leukemoid” episodes. In individuals suffering from TAR syndrome, numerous orthopedic techniques may also be recommended, such as corrective braces, splints, and/or certain surgical measures. Treatment with specific medications, surgical intervention, or other measures may be necessary for affected individuals with congenital heart defects.  Thus, all these treatment options enhance the market growth.

Restraints/Challenges

• High Cost of Treatment

The huge cost associated with the treatment processes involving surgeries and certain therapies cost quite high; thus, this increasing cost hinders the market growth.

This thrombocytopenia-absent radius (TAR) syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thrombocytopenia-absent radius (TAR) syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Thrombocytopenia-Absent Radius (TAR) Syndrome Market Scope

The thrombocytopenia-absent radius (TAR) syndrome market is segmented on the basis of treatment, diagnosis, age of onset, dosage, route of administration, end-users and distribution channel . The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Surgery
• Intrauterine Platelet Transfusion
• Genetic Counseling
• Occupational Therapy
• Physiotherapy
• Others

Diagnosis

• Blood Tests
• Genetic Testing
• Ultrasonography
• X-Ray
• Others​​​​​​​

Age of Onset

• Neonatal
• Antenatal

Dosage

• Injection
• Tablets
• Others

Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Thrombocytopenia-Absent Radius (TAR) Syndrome Regional Analysis/Insights

The thrombocytopenia-absent radius (TAR) syndrome market is analyzed and market size insights and trends are provided by treatment, diagnosis, age of onset, dosage, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the thrombocytopenia-absent radius (TAR) syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period because of the huge presence of major market players, high disposable income and well-developed healthcare infrastructure in this region. 

Asia-Pacific is considered to grow over the coming years because of the growing patient pool, increasing investment in the healthcare sector and rising government support.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Thrombocytopenia-Absent Radius (TAR) Syndrome Share Analysis

The thrombocytopenia-absent radius (TAR) syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to thrombocytopenia-absent radius (TAR) syndrome market

Key players operating in the thrombocytopenia-absent radius (TAR) syndrome market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott, Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Abbott(U.S.)
• Biomerieux (France)
• Bio-Rad Laboratories, Inc. (U.S.)
• BioMarin (U.S.)
• Quotient Suisse SA (Switzerland)
• BAG Health Care GmbH (Germany
• DiaSorin S.p.A (Italy)
• Thermo Fisher Scientific Inc. (U.S.)
• Siemens Healthcare GmbH (Germany)
• Hologic, Inc. (U.S.)
• Dynatronics Corporation (U.S.)
• Ito Co., Ltd (Japan)

SKU-67572